1. Hong Kong Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Sirnaomics Ltd.

Sirnaomics Ltd.

HHKEX:2257
4.08
HKD
-0.02
(-0.61%)
816.08MMarket Cap
Apr 01Next Earn
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
0.02
- -
- -
Basic EPS, GAAP
-0.19
-0.5
-14.3
-1.16
-1.03
-0.66
-0.15
- -
Free Cash Flow per Basic Share
-0.18
-0.24
-4.22
-1.41
-0.95
-0.26
-0.1
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-0.59
-1.07
2.4
1.39
0.46
-0.02
-0.09
-0.09
Tangible Book Value per Share
-0.59
-1.08
2.39
1.38
0.45
-0.02
-0.1
-0.1
Basic Weighted Avg Shares
88
88
15
76
76
77
94
94
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
2
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
-2,018.22
- -
- -
Depreciation Expense
1
1
2
4
6
6
2
- -
Net Income, GAAP
-16
-44
-213
-88
-79
-51
-14
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
-2,889.93
- -
- -
Working Capital
19
11
208
103
15
-18
-23
-23
LT Debt
2
2
6
9
8
7
7
7
Total Equity
-49
-94
210
112
24
-16
-24
-24
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
-52.93
-97.03
- -
- -
- -

Capital Structure

USD

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
1
1
2
LT Borrowings
- -
- -
- -
LT Finance Leases
7
6
7
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
104
104
106
Market Capitalization
46
60
105

Working Capital

USD

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
19
14
15
Cash, Cash Equivalents & STI
12
7
14
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
37
34
38
Payables & Accruals
- -
- -
- -
ST Debt
1
1
2
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-112.14%
53.04%
Free Cash Flow
- -
21.89%
-53.35%
Net Income, GAAP
- -
42.13%
-71.97%
Sales/Revenue/Turnover
- -
- -
-100%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

USD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
2
2025
- -
- -
- -

Semi-annual Earnings Per Share

USD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
-1.03
2024
- -
- -
-0.66
2025
- -
- -
-0.15

Semi-annual Dividends Per Share

USD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Hong Hui Pan
Full Time Employees
37
Sector
Health technology
Industry
Biotechnology
Address
20511 Seneca Meadows Parkway Hong Kong MD Hong Kong 20876
IPO Date
Dec 30, 2021
Website
sirnaomics.com
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
Sirnaomics Ltd. (2257.HK) is a clinical-stage biopharmaceutical company that discovers, develops and commercializes ribonucleic acid interference (RNAi) therapeutics targeting unmet medical needs in oncology, fibrosis, cardiometabolic diseases, complement-mediated diseases, medical aesthetics and viral infections. The company offers a robust pipeline of over 10 drug candidates delivered via proprietary platforms including Polypeptide Nanoparticle (PNP) and the next-generation GalAhead GalNAc conjugation technology; lead products comprise STP705, a topical siRNA therapy for non-melanoma skin cancers such as squamous cell carcinoma in situ and keloids as well as focal fat reduction in medical aesthetics; STP707, a systemic siRNA therapeutic for solid tumors including liver, kidney, pancreatic, breast, colorectal and melanoma cancers; STP122G, the first GalAhead candidate in Phase I for anticoagulation disorders targeting Factor XI; STP125G for hypertriglyceridemia; STP144G for complement-mediated diseases; STP247G for complement immunologic diseases; STP237G for hypertension combined with familial hypertriglyceridemia; and STP136G for hypertension. Founded in 2007 and headquartered in Wan Chai, Hong Kong, with key subsidiaries in Germantown, Maryland, USA (including Sirnaomics USA and RNAimmune), Suzhou and Guangzhou, China, the company maintains R&D and manufacturing operations across the United States, Greater China and the Asia-Pacific region. Recent developments include a strategic HKD 138 million equity investment from Bloomage Biotech in September 2025 representing approximately 9.44% ownership to accelerate aesthetics and longevity RNAi programs notably STP705 fat reduction alongside new precision-delivery collaborations integrating hyaluronic acid expertise; a prior HKD 58.9 million subscription from Dr. Poon Hung Fai in October 2024 to bolster R&D and operations; expansion of the Guangzhou GMP facility for full-scale production of pipeline injectables including STP707 batches; IND preparations for STP125G and STP144G in 2024; advancement of STP122G into Phase I trials; and establishment of an R&D center at Hong Kong Science Park in 2023 with subsidiaries RNAimmune and EDIRNA.